What Happened?
Shares of diagnostics company Guardant Health (NASDAQ: GH) jumped 5.9% in the afternoon session after the company announced that real-world evidence from its InfinityAI platform contributed to the approval of the cancer drug ENHERTU® in Japan.
The drug, developed by Daiichi Sankyo, was approved for treating patients with specific types of HER2-positive advanced or recurrent solid cancers. This development highlighted the increasing role of AI-powered, real-world data in the drug approval process, which could help get new treatments to patients faster. The news signaled a significant validation of Guardant's technology and its application in precision oncology.
Is now the time to buy Guardant Health? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Guardant Health’s shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 4 days ago when the stock dropped 3% on the news that major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as investors reacted to escalating uncertainty tied to the U.S.-Iran conflict and policy deadlines set by the Trump administration. Markets dislike unpredictability, and these fears were amplified, raising concerns of prolonged conflict and rising oil prices. This negative outlook reflected in consumer confidence, with the University of Michigan's sentiment index sliding to a three-month low.
Guardant Health is down 9.2% since the beginning of the year, and at $92.41 per share, it is trading 21.2% below its 52-week high of $117.28 from January 2026. Investors who bought $1,000 worth of Guardant Health’s shares 5 years ago would now be looking at only $605.38.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
